Longwood Capital Partners
Latest statistics and disclosures from Acuta Capital Partners's latest quarterly 13F-HR filing:
- Top 5 stock holdings are REPL, SRPT, TSHA, APLS, AADI, and represent 83.34% of Acuta Capital Partners's stock portfolio.
- Added to shares of these 10 stocks: REPL (+$267M), SRPT (+$221M), TSHA (+$12M), RYZB (+$7.6M), CRNX, HLVX, ALKS, CNTA, VTYX, RCKT.
- Started 16 new stock positions in CLRB, GLYC, BCLI, SRPT, MRNS, GPCR, ANTX, IONS, MRSN, CNTA. LPTX, ETNB, TSHA, REPL, RYZB, CRNX.
- Reduced shares in these 10 stocks: Iveric Bio (-$5.2M), ARGX, CLNN, GHRS, ROIV, TERN, APLS, MORF, ARWR, EYPT.
- Sold out of its positions in ARGX, ARWR, CLNN, Iveric Bio, MORF, SVRA, GHRS, ROIV.
- Acuta Capital Partners was a net buyer of stock by $499M.
- Acuta Capital Partners has $622M in assets under management (AUM), dropping by 321.26%.
- Central Index Key (CIK): 0001582844
Tip: Access up to 7 years of quarterly data
Positions held by Longwood Capital Partners consolidated in one spreadsheet with up to 7 years of data
Download as csv Download as ExcelPortfolio Holdings for Acuta Capital Partners
Acuta Capital Partners holds 43 positions in its portfolio as reported in the September 2023 quarterly 13F filing
Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
---|---|---|---|---|---|---|
Replimune Group Call Option (REPL) | 42.9 | $267M | NEW | 151k | 1766.00 |
|
Sarepta Therapeutics Call Option (SRPT) | 35.6 | $221M | NEW | 16k | 13783.00 |
|
Taysha Gene Therapies Com Shs (TSHA) | 1.9 | $12M | NEW | 3.8M | 3.16 |
|
Apellis Pharmaceuticals (APLS) | 1.5 | $9.3M | -17% | 245k | 38.04 |
|
Aadi Bioscience (AADI) | 1.4 | $9.0M | 1.8M | 4.84 |
|
|
Praxis Precision Medicines I | 1.2 | $7.7M | +5% | 4.5M | 1.71 |
|
Rayzebio (RYZB) | 1.2 | $7.6M | NEW | 345k | 22.20 |
|
Rocket Pharmaceuticals (RCKT) | 1.2 | $7.4M | +18% | 362k | 20.49 |
|
Ventyx Biosciences (VTYX) | 1.1 | $7.1M | +39% | 205k | 34.73 |
|
Disc Medicine (IRON) | 1.0 | $6.5M | 138k | 46.98 |
|
|
Kura Oncology (KURA) | 1.0 | $6.4M | 702k | 9.12 |
|
|
Cymabay Therapeutics (CBAY) | 1.0 | $6.2M | -2% | 418k | 14.91 |
|
Vaxcyte (PCVX) | 1.0 | $6.2M | 121k | 50.98 |
|
|
Immunovant (IMVT) | 0.8 | $5.0M | -8% | 129k | 38.39 |
|
Syndax Pharmaceuticals (SNDX) | 0.7 | $4.3M | 297k | 14.52 |
|
|
Hillevax (HLVX) | 0.6 | $3.6M | +328% | 270k | 13.45 |
|
Alkermes SHS (ALKS) | 0.6 | $3.5M | +183% | 127k | 28.01 |
|
Miragen Therapeutics (VRDN) | 0.6 | $3.4M | 224k | 15.34 |
|
|
Celldex Therapeutics Com New (CLDX) | 0.5 | $3.4M | 122k | 27.52 |
|
|
Crinetics Pharmaceuticals In (CRNX) | 0.4 | $2.8M | NEW | 94k | 29.74 |
|
Terns Pharmaceuticals (TERN) | 0.4 | $2.8M | -42% | 555k | 5.03 |
|
Eyepoint Pharmaceuticals Com New (EYPT) | 0.4 | $2.4M | -21% | 300k | 7.99 |
|
Ikena Oncology (IKNA) | 0.4 | $2.4M | 551k | 4.33 |
|
|
Centessa Pharmaceuticals Sponsored Ads (CNTA) | 0.3 | $2.1M | NEW | 323k | 6.47 |
|
Olema Pharmaceuticals (OLMA) | 0.3 | $1.9M | +44% | 153k | 12.35 |
|
Verastem Com New (VSTM) | 0.3 | $1.9M | -23% | 230k | 8.13 |
|
Enliven Therapeutics (ELVN) | 0.2 | $1.4M | 104k | 13.66 |
|
|
Dyne Therapeutics (DYN) | 0.2 | $1.3M | +100% | 147k | 8.96 |
|
Kronos Bio (KRON) | 0.2 | $934k | +128% | 719k | 1.30 |
|
Aclaris Therapeutics (ACRS) | 0.1 | $834k | 122k | 6.85 |
|
|
Brainstorm Cell Therapeutics Com New Put Option (BCLI) | 0.1 | $825k | NEW | 2.5k | 330.00 |
|
Biomea Fusion (BMEA) | 0.1 | $550k | 40k | 13.76 |
|
|
89bio (ETNB) | 0.1 | $522k | NEW | 34k | 15.44 |
|
Ionis Pharmaceuticals (IONS) | 0.1 | $513k | NEW | 11k | 45.36 |
|
Leap Therapeutics Com New (LPTX) | 0.1 | $489k | NEW | 354k | 1.38 |
|
Rezolute Com New (RZLT) | 0.1 | $409k | -16% | 310k | 1.32 |
|
Cellectar Biosciences Com New (CLRB) | 0.1 | $320k | NEW | 121k | 2.64 |
|
Structure Therapeutics Sponsored Ads (GPCR) | 0.0 | $252k | NEW | 5.0k | 50.42 |
|
An2 Therapeutics (ANTX) | 0.0 | $214k | NEW | 13k | 16.08 |
|
Marinus Pharmeceuticals Com New (MRNS) | 0.0 | $157k | NEW | 20k | 8.05 |
|
Mersana Therapeutics (MRSN) | 0.0 | $127k | NEW | 100k | 1.27 |
|
Glycomimetics (GLYC) | 0.0 | $41k | NEW | 28k | 1.50 |
|
Nuvation Bio *w Exp 07/07/2027 (NUVB.WS) | 0.0 | $9.1k | 91k | 0.10 |
|
Past Filings by Acuta Capital Partners
SEC 13F filings are viewable for Acuta Capital Partners going back to 2014
- Acuta Capital Partners 2023 Q3 filed Nov. 14, 2023
- Acuta Capital Partners 2023 Q2 filed Aug. 14, 2023
- Acuta Capital Partners 2023 Q1 filed May 15, 2023
- Acuta Capital Partners 2022 Q4 filed Feb. 14, 2023
- Acuta Capital Partners 2022 Q3 filed Nov. 14, 2022
- Acuta Capital Partners 2022 Q2 filed Aug. 15, 2022
- Acuta Capital Partners 2022 Q1 filed May 16, 2022
- Acuta Capital Partners 2021 Q4 filed Feb. 14, 2022
- Acuta Capital Partners 2021 Q3 filed Nov. 15, 2021
- Acuta Capital Partners 2021 Q2 filed Aug. 16, 2021
- Acuta Capital Partners 2021 Q1 filed May 17, 2021
- Acuta Capital Partners 2020 Q4 filed Feb. 16, 2021
- Acuta Capital Partners 2020 Q3 filed Nov. 16, 2020
- Acuta Capital Partners 2020 Q2 filed Aug. 14, 2020
- Acuta Capital Partners 2020 Q1 filed May 15, 2020
- Acuta Capital Partners 2019 Q4 filed Feb. 14, 2020